The Technical Analyst
Personalis Inc [PSNL]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Personalis Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.23% $1.200
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 60.60 mill |
| EPS: | -2.25 |
| P/E: | -0.530 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 50.50 mill |
| Avg Daily Volume: | 0.355 mill |
| RATING 2024-04-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.530 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.530 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.064 - 1.336 ( +/- 11.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Hall Christopher M | Buy | 400 000 | Stock Option (right to buy) |
| 2024-03-15 | Chen Richard | Buy | 175 000 | Stock Option (right to buy) |
| 2024-03-15 | Tachibana Aaron | Buy | 175 000 | Stock Option (right to buy) |
| 2024-03-15 | Moore Stephen Michael | Buy | 100 000 | Stock Option (right to buy) |
| 2024-03-01 | Myers Woodrow A Jr | Buy | 10 000 | Common Stock |
| INSIDER POWER |
|---|
| -62.02 |
| Last 98 transactions |
| Buy: 3 908 824 | Sell: 9 802 248 |
Forecast:
16:00 - $1.200
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.200
Forecast 2: 16:00 - $1.200
Forecast 3: 16:00 - $1.200
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.200 (-3.23% ) |
| Volume | 0.360 mill |
| Avg. Vol. | 0.355 mill |
| % of Avg. Vol | 101.45 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PSNL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| ZAP.OL | Apr 18 - 04:50 | NOK13.90 |
| CODE.OL | Apr 18 - 04:49 | 0.900 |
| AKBM.OL | Apr 18 - 04:45 | NOK68.40 |
| BGBIO.OL | Apr 18 - 04:44 | NOK0.161 |
| NEXT.OL | Apr 18 - 04:44 | NOK8.62 |
| SVEG.OL | Apr 18 - 04:43 | NOK118.40 |
| NORSE.OL | Apr 18 - 04:42 | NOK8.04 |
| WWIB.OL | Apr 18 - 04:42 | NOK355.00 |
| OETHUSD | Apr 18 - 04:53 | 2 956.98 |
| STB.OL | Apr 18 - 04:40 | NOK94.50 |
Latest Press Releases
2024-03-28 16:01:00 - Press Release
Personalis To Present At The 23rd Annual Needham Virtual Healthcare Conference
Fremont, calif.--(business wire)--personalis, inc. (nasdaq: psnl), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd annual needham virtual healthcare conference on wednesday, april 10 at 1:30 p.m. eastern time. about personalis, inc. at personalis, we are transforming the active management of cancer through breakthrough personalized testing. we aim to drive a new paradigm for cancer management, guiding care from biopsy through the life.
2024-03-28 09:00:00 - Press Release
Data Showcasing Next Personal Mrd Test To Be Presented At The 2024 American Association For Cancer Research (aacr) Annual Meeting
Fremont, calif.--(business wire)--personalis, inc. (nasdaq: psnl), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company's next personal® whole genome-based, tumor-informed assay for ultra-sensitive ctdna detection will be presented at the american association for cancer research (aacr) annual meeting, taking place in san diego, california, april 5-10, 2024. “personalis is excited to present data showing ou.
2024-03-26 09:00:00 - Press Release
Personalis Announces Publication Validating Next Personal® Test For Ultra-sensitive Mrd Detection And Cancer Treatment Response Monitoring
Fremont, calif.--(business wire)--personalis, inc. (nasdaq: psnl), a leader in advanced genomics for precision oncology, today announced a new publication validating the company's next personal test, an ultra-sensitive, tumor-informed circulating tumor dna (ctdna) assay. next personal is designed to help detect minimal residual disease (mrd), monitor therapy response, and identify recurrence with high analytical sensitivity and accuracy, enhancing the decision-making process and ultimately impr.
2024-03-19 16:43:00 - Press Release
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fremont, calif.--(business wire)--personalis, inc. (nasdaq: psnl), a leader in advanced genomics for precision oncology, today announced that the compensation committee of its board of directors granted, on november 15, 2023 and march 15, 2024, non-qualified stock options to purchase an aggregate of 41,500 shares of its common stock to ten new employees under personalis' 2020 inducement plan. the 2020 inducement plan is used exclusively for the grant of equity awards to individuals who were not.
2024-02-14 16:01:00 - Press Release
Personalis To Announce Fourth Quarter And Full Year 2023 Financial Results
Fremont, calif.--(business wire)--personalis, inc. (nasdaq: psnl), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on wednesday, february 28, 2024. in conjunction with the release, personalis will host a conference call and webcast that day at 2:00 p.m. pacific time / 5:00 p.m. eastern time to discuss its financial results and recent highlights. interested parties may access the call by dialing 877-451-6152 f.
Latest News
2024-02-28 21:20:23 - Seeking Alpha
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
2024-01-31 16:01:00 - Business Wire
Personalis to Participate at Upcoming Investor Conferences
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Participating on Tuesday, February 13, 2024 at The Cliff Lodge in Snowbird, UT 44th Annual Cowen Healthcare Conference Presenting on Wednesday, March 6, 2024 at 12:50 p.m. Eastern Time at the Boston Marriott Copley P.
2023-11-07 23:04:10 - Seeking Alpha
Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Research and Development Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Mark Massaro - VTIG Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call.
2023-08-29 16:01:00 - Business Wire
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton New York. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradig.
2023-04-19 16:01:00 - Business Wire
Personalis to Announce First Quarter 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
2023-04-17 13:11:50 - Seeking Alpha
Personalis: Revisiting The Investment Thesis
Today, we put diagnostic firm Personalis, Inc. back in the spotlight as the shares go for less than the company's net cash on the balance sheet. The company has brought in a new CEO and announced significant cost saving measures.
2023-02-28 13:33:27 - Zacks Investment Research
Personalis (PSNL) Upgraded to Buy: Here's What You Should Know
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-02-23 23:36:06 - Seeking Alpha
Personalis, Inc. (PSNL) Q4 2022 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q4 2022 Results Conference Call February 23, 2023 5:00 PM ET Company Participants Caroline Corner - Investor Relations Aaron Tachibana - Interim Chief Financial Officer and Chief Financial Officer Chris Hall - President Rich Chen - Chief Medical Officer, and SVP of R&D Conference Call Participants Joseph Flanagan - Cowen Vivian Bais - BTIG Arthur He - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Personalis Fourth Quarter 2022 Earnings Conference Call.
2023-02-04 11:00:00 - PennyStocks
A Short Guide to Making Money With Penny Stocks in 2023
Use these tips for making money with penny stocks The post A Short Guide to Making Money With Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-17 21:10:37 - Seeking Alpha
Personalis: Looking For A Potential Turnaround In 2023
Personalis is a small-cap cancer genomics company with a next-gen cancer diagnostics platform whose stock has lost over 80% of its value over the past twelve months. Personalis is reporting substantial losses, however, the company's strong balance sheet could provide them with enough runway to prove they are a legitimate player in a $30+B market.